Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic : 25I-NBOMe or 25N-NBOMe or Sumatriptan / Naproxen

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
None (2) · Treximet (1)
classes:
Classic Psychedelic (2) · Phenethylamine (2) · Research material (2) · [[:Category:Antimigraine_agents|Antimigraine agent]] (1) · [[:Category:Fixed-dose_combinations|Fixed-dose combination]] (1) · [[:Category:NSAIDs|NSAID (naproxen)]] (1) · [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] (1)
mechanism:
5-HT2A agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · '"`UNIQ--vote-000015CE-QINU`"' The dual-mechanism design exploits the inflammatory component of migraine that triptan monotherapy does not fully address. Risk of serotonin syndrome with SSRIs/SNRIs is theoretical but generally not seen clinically at triptan doses'"`UNIQ--ref-000015CF-QINU`"'. (1)
uses:
None (2) · '"`UNIQ--vote-000015D0-QINU`"' (1)
starting dose:
None (2) · 1 tablet (85/500 mg sumatriptan/naproxen) PO at migraine onset; may repeat after 2 hours if needed; maximum 2 tablets per 24 hours (1)
preparations:
None (2) · 85 mg sumatriptan / 500 mg naproxen sodium tablets; lower-dose 10/60 mg pediatric (Treximet pediatric) (1)
fda max:
None (2) · 2 tablets per 24 hours; ≤4 days per month to avoid medicine-overuse headache (1)
routes:
None (2) · Oral (1)
onset:
None (2) · Headache relief at 30-60 minutes (1)
duration:
None (2) · 4-8 hours (1)
halflife:
None (2) · Sumatriptan ~2.5 hours; naproxen 12-15 hours'"`UNIQ--ref-000015D1-QINU`"' (1)
bioavailability:
None (2) · Sumatriptan ~15% (oral; substantial first-pass); naproxen ~95%'"`UNIQ--ref-000015D2-QINU`"' (1)
pregnancy:
None (2) · Avoid; NSAID-class restriction after 20 weeks (FDA 2020) and limited triptan pregnancy data.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)
legal:
None (2) · [[USLegal:Prescription only|Rx-only]] in US. NSAID-class '''Boxed Warning''' for CV thrombotic events and GI bleeding; triptans contraindicated in coronary artery disease, peripheral vascular disease, uncontrolled hypertension, and recent ergot or MAOI use'"`UNIQ--ref-000015D3-QINU`"' (1)

Showing below up to 3 results in range #1 to #3.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"